For more than 15 years, researchers at the U-M Rogel Cancer Center have been pursuing a way to stop the mutations that drive Ewing sarcoma. Progress was slow until a fresh look at a familiar group of drugs revealed something they had been missing. The shift in perspective may have opened a promising new path forward.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.